Krystal Biotech, Inc.
KRYS
Rangering i aksjer
#2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Aksjekurs
$326.41
Markedsverdi
$9.66B
Endring (1 dag)
1.92%
Endring (1 år)
66.57%
Land
US
Handel Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Antall utestående aksjer for Krystal Biotech, Inc. (KRYS)
Antall utestående aksjer per June 2026: 29.53M
Ifølge Krystal Biotech, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 29.53M. Ved slutten av December 2023 hadde selskapet 27.15M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Krystal Biotech, Inc. (KRYS) fra 2016 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 29.53M | 3.28% |
| 2024 | 28.59M | 5.30% |
| 2023 | 27.15M | 6.52% |
| 2022 | 25.49M | 14.85% |
| 2021 | 22.20M | 18.15% |
| 2020 | 18.79M | 18.15% |
| 2019 | 15.90M | 41.93% |
| 2018 | 11.20M | 108.99% |
| 2017 | 5.36M | 25.38% |
| 2016 | 4.28M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 759.83% |
US
|
|
| 396.00M | 1,241.05% |
US
|
|
| 478.91M | 1,521.84% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 110.59% |
NL
|
